HOME > ARCHIVE
ARCHIVE
- METI to Support 386 Technological Development Projects
April 1, 2002
- New Standard Prices for Medical Materials Announced
April 1, 2002
- Takeda's New Invoice Prices More Closely Reflect Price Reductions Than Before
April 1, 2002
- REGULATORY NEWS IN BRIEF
April 1, 2002
- JIRA Is Enthusiastic about Forming New Medical Device Approval System
April 1, 2002
- REGULATORY NEWS IN BRIEF
March 25, 2002
- Supply of Good-quality Drug Information Should Be Promoted: JPMA Seminar
March 25, 2002
- Objective of Immediate PMS Is to Promote Proper Use of Drugs: JAPIC Seminar
March 25, 2002
- JPMA, CROs, SMOs to Jointly Solve Problems with Clinical Trials
March 25, 2002
- Simvastatin Inhibits Coronary Events in 3-lipid Abnormality Group: Banyu Seminar
March 25, 2002
- Sankyo, Yamanouchi Explain Genomics Strategies: Nomura Bio Conference 2002
March 25, 2002
- AstraZeneca's Development Capability in Japan at Int'l Level: R&D Executives
March 25, 2002
- WORLD NEWS IN BRIEF
March 25, 2002
- NTT DATA to Provide Free Software for Compressing Genome Data
March 25, 2002
- FDA Approves Gen-Probe's HIV-1, HCV Blood Screening Test
March 25, 2002
- Pharmagene Forms Its First Indication Switch Alliance with Sosei
March 25, 2002
- NHI Price Revision to Hit Companies Differently
March 25, 2002
- Takara Sets Up Target Protein Mass Production System in Tandem with UMDNJ
March 25, 2002
- Sales of Lipitor Increase by 216% to \40 Bil.: Mr Bootes of Pfizer
March 25, 2002
- Kyowa Hakko Discovers New Type of Mesenchymal Stem Cell
March 25, 2002
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
